N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Microbiome and Sarcopenia in Patients With Liver Cirrhosis

Sponsor: Medical University of Graz • ClinicalTrials.gov ID: NCT03080129

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients. Malnutrition and sarcopenia are associated with an increased risk of complications and mortality. In cirrhosis the gut microbiome is altered leading to increased gut permeability, bacterial translocation and inflammation. Since the microbiome is involved in nutrient uptake and metabolism, it is hypothesized that microbiome alterations contribute to sarcopenia. A prospective controlled cohort study to investigate the interrelation of microbiome changes and sarcopenia in cirrhosis will be conducted. Furthermore the effect of nutritional interventions on the microbiome in cirrhosis will be studied. From this study information on how the gut microbiome composition and sarcopenia are associated in cirrhosis and if modulation of the gut microbiome by nutritional interventions is feasible will be collected.

Interventions

  • Fresubin energy (Dietary supplement)
    dietary protein energy supplement

Eligibility criteria

Inclusion Criteria: * Hospitalized patients for any reason with clinical/radiological/histological diagnosis of cirrhosis * Age \>18y * Informed consent * CT/MRI scan within +/-14 days of the baseline study visit Exclusion Criteria: * Hepatic encephalopathy \> grade 2 and or other cognitive disorder not allowing informed consent * advanced hepatocellular carcinoma * Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

Conditions

Sarcopenia Liver Cirrhosis

Locations

  • Medical University Graz — Graz, Austria
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record